vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -161.8%, a 156.7% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -14.2%). READING INTERNATIONAL INC produced more free cash flow last quarter ($4.1M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
IBRX vs RDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $50.3M |
| Net Profit | $-61.9M | $-2.6M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | -1.9% |
| Net Margin | -161.8% | -5.1% |
| Revenue YoY | 407.0% | -14.2% |
| Net Profit YoY | -4.7% | -14.5% |
| EPS (diluted) | $-0.06 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $50.3M | ||
| Q3 25 | $32.1M | $52.2M | ||
| Q2 25 | $26.4M | $60.4M | ||
| Q1 25 | $16.5M | $40.2M | ||
| Q4 24 | $7.6M | $58.6M | ||
| Q3 24 | $6.1M | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | — | $45.1M |
| Q4 25 | $-61.9M | $-2.6M | ||
| Q3 25 | $-67.3M | $-4.2M | ||
| Q2 25 | $-92.6M | $-2.7M | ||
| Q1 25 | $-129.6M | $-4.8M | ||
| Q4 24 | $-59.2M | $-2.2M | ||
| Q3 24 | $-85.7M | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | — | $-13.2M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | -1.9% | ||
| Q3 25 | -173.5% | -0.6% | ||
| Q2 25 | -269.8% | 4.8% | ||
| Q1 25 | -390.1% | -17.2% | ||
| Q4 24 | -919.0% | 2.6% | ||
| Q3 24 | -1314.3% | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -16.7% |
| Q4 25 | -161.8% | -5.1% | ||
| Q3 25 | -209.8% | -8.0% | ||
| Q2 25 | -350.3% | -4.4% | ||
| Q1 25 | -784.9% | -11.8% | ||
| Q4 24 | -783.4% | -3.8% | ||
| Q3 24 | -1404.0% | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | — | -29.4% |
| Q4 25 | $-0.06 | $-0.11 | ||
| Q3 25 | $-0.07 | $-0.18 | ||
| Q2 25 | $-0.10 | $-0.12 | ||
| Q1 25 | $-0.15 | $-0.21 | ||
| Q4 24 | $-0.08 | $-0.11 | ||
| Q3 24 | $-0.14 | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | — | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $-500.5M | $-18.2M |
| Total Assets | $501.9M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $10.5M | ||
| Q3 25 | $257.8M | $8.1M | ||
| Q2 25 | $153.7M | $9.1M | ||
| Q1 25 | $61.6M | $5.9M | ||
| Q4 24 | $149.8M | $12.4M | ||
| Q3 24 | $130.4M | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-500.5M | $-18.2M | ||
| Q3 25 | $-524.3M | $-12.1M | ||
| Q2 25 | $-570.7M | $-7.7M | ||
| Q1 25 | $-591.4M | $-8.1M | ||
| Q4 24 | $-489.1M | $-4.4M | ||
| Q3 24 | $-745.1M | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | — | $18.0M |
| Q4 25 | $501.9M | $434.9M | ||
| Q3 25 | $519.0M | $435.2M | ||
| Q2 25 | $402.1M | $438.1M | ||
| Q1 25 | $303.8M | $441.0M | ||
| Q4 24 | $382.9M | $471.0M | ||
| Q3 24 | $364.6M | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | — | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $4.3M |
| Free Cash FlowOCF − Capex | $-71.3M | $4.1M |
| FCF MarginFCF / Revenue | -186.2% | 8.2% |
| Capex IntensityCapex / Revenue | 2.4% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $4.3M | ||
| Q3 25 | $-68.9M | $295.0K | ||
| Q2 25 | $-79.7M | $1.6M | ||
| Q1 25 | $-85.9M | $-7.7M | ||
| Q4 24 | $-85.1M | $8.0M | ||
| Q3 24 | $-98.8M | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | — | $-2.8M |
| Q4 25 | $-71.3M | $4.1M | ||
| Q3 25 | $-69.6M | $-246.0K | ||
| Q2 25 | $-80.8M | $1.2M | ||
| Q1 25 | $-87.0M | $-8.0M | ||
| Q4 24 | $-87.3M | $7.0M | ||
| Q3 24 | $-101.6M | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-4.7M |
| Q4 25 | -186.2% | 8.2% | ||
| Q3 25 | -217.2% | -0.5% | ||
| Q2 25 | -305.9% | 1.9% | ||
| Q1 25 | -526.9% | -19.8% | ||
| Q4 24 | -1155.4% | 12.0% | ||
| Q3 24 | -1663.2% | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | — | -10.4% |
| Q4 25 | 2.4% | 0.3% | ||
| Q3 25 | 2.3% | 1.0% | ||
| Q2 25 | 4.1% | 0.6% | ||
| Q1 25 | 6.8% | 0.6% | ||
| Q4 24 | 28.0% | 1.7% | ||
| Q3 24 | 45.7% | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 4.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
